Topical antimicrobial treatment of acne vulgaris: An evidence-based review

American Journal of Clinical Dermatology

Volumn 13, Issue 3, 2012, Pages 141-152

  Gamble, Ryan ^a   Dunn, Jeff ^a   Dawson, Annelise ^a   Petersen, Brian ^a   McLaughlin, Lauren ^b   Small, Alison ^c   Kindle, Scott ^d   Dellavalle, Robert P ^a,e  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Rocky Vista University   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e Affairs Medical Center   (United States)

Author keywords

Acne vulgaris; Anti infectives; Antibacterials; Azelaic acid; Benzoyl peroxide; Dapsone; Retinoids; Salicylic acid; Topical; Zinc

Indexed keywords

ADAPALENE; ALLYLAMINE; ANTIBIOTIC AGENT; AZELAIC ACID; BENZOYL PEROXIDE; CLINDAMYCIN; DAPSONE; ERYTHROMYCIN; MINOCYCLINE; OXYTETRACYCLINE; RETINOIC ACID; RETINOID; SALICYLIC ACID; SULFACETAMIDE; TAZAROTENE; TETRACYCLINE; ZINC ACETATE;

ACNE VULGARIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRY SKIN; EMBASE; ERYTHEMA; EVENING DOSAGE; HUMAN; KERATINOCYTE; MEDLINE; META ANALYSIS (TOPIC); MONOTHERAPY; MORNING DOSAGE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; PSEUDOMEMBRANOUS COLITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN ABRASION; SKIN BURNING SENSATION; UNSPECIFIED SIDE EFFECT;

EID: 84859394780     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11597880-000000000-00000     Document Type: Review

References (94)

1. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60 (5 Suppl.): S1-50
2. Tan HH. Topical antibacterial treatments for acne vulgaris: comparative review and guide to selection. Am J Clin Dermatol 2004; 5 (2): 79-84
3. Brown SK, Shalita AR. Acne vulgaris. Lancet 1998; 351 (9119): 1871-6
4. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007; 56 (4): 651-63
5. Institute for Clinical Systems Improvement. Neely C, Davis M, Lee J, et al. ICSI acne guidelines, 2006 [online]. Available from URL:. http://www.icsiorg/acne/acne-management-3.html [Accessed 2011 Apr 17]
6. Patel M, Bowe WP, Heughebaert C, et al. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. J Drugs Dermatol 2010; 9 (6): 655-64
7. Purdy S, de Berker D. Acne vulgaris. Clin Evid (Online). Epub 2011 Apr 12
8. What role for topical antibacterials in acne? Drug Ther Bull 2010; 48 (12): 141-4
9. Dutil M. Benzoyl peroxide: enhancing antibiotic efficacy in acne management. Skin Therapy Lett 2010; 15 (10): 5-7
10. Krakowski AC, Stendardo S, Eichenfield LF. Practical considerations in acne treatment and the clinical impact of topical combination therapy. Pediatr Dermatol 2008; 25 Suppl. 1: 1-14
11. Fakhouri T, Yentzer BA, Feldman SR. AdVancement in benzoyl peroxidebased acne treatment: methods to increase both efficacy and tolerability. J Drugs Dermatol 2009; 8 (7): 657-61
12. Del Rosso JQ, Kim GK. Topical antibiotics: therapeutic value or ecologic mischief? Dermatol Ther 2009; 22 (5): 398-406
13. Del Rosso JQ, Leyden JJ, Thiboutot D, et al. Antibiotic use in acne vulgaris and rosacea: clinical considerations and resistance issues of significance to dermatologists. Cutis 2008; 82 (2 Suppl. 2): 5-12
14. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis 2007; 79 (6 Suppl.): 9-25
15. Tan AW, Tan HH. Acne vulgaris: a review of antibiotic therapy. Expert Opin Pharmacother 2005; 6 (3): 409-18
16. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005; 153 (2): 395-403
17. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. Epub 2011 Aug 29
18. Chivot M. Retinoid therapy for acne. A comparative review. Am J Clin Dermatol 2005; 6 (1): 13-9
19. Thiboutot D, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1%gel in the treatment of acne vulgaris. J Drugs Dermatol 2008; 7 (6 Suppl.): s3-10
20. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (1 Suppl.): S1-37
21. Gollnick H, Schramm M. Topical therapy in acne. J Eur Acad Dermatol Venereol 1998; 11 Suppl. 1: S8-12; discussion S28-9
22. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003; 49 (3 Suppl.): S200-10
23. Mills OH, Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol 1978; 58 (6): 555-7
24. Martin B, Meunier C, Montels D, et al. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol 1998; 139 Suppl. 52: 8-11
25. Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with combination clindamycin/benzoyl peroxide gel compared with clindamycin gel benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997; 37 (4): 590-5
26. Bojar RA, Eady EA, Jones CE, et al. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994; 130 (3): 329-36
27. Mills OH, Kligman AM, Pochi P, et al. Comparing 2.5%, 5%, and 10%benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol 1986; 25 (10): 664-7
28. Lyons RE. Comparative effectiveness of benzoyl peroxide and tretinoin in acne vulgaris. Int J Dermatol. 1978; 17 (3): 246-51
29. Hughes BR, Norris JF, Cunliffe WJ. A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5%and placebo in patients with acne. Clin Exp Dermatol 1992; 17 (3): 165-8
30. Bucknall JH, Murdoch PN. Comparison of tretinoin solution and benzoyl peroxide lotion in the treatment of acne vulgaris. Curr Med Res Opin 1977;5 (3): 266-8
31. Handojo I. Retinoic acid cream (Airol cream) and benzoyl-peroxide in the treatment of acne vulgaris. Southeast Asian J Trop Med Public Health 1979; 10 (4): 548-51
32. Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne management. Pediatrics 2006; 118 (3): 1188-99
33. Weinberg JM. The utility of benzoyl peroxide in hydrophase base (Brevoxyl) in the treatment of acne vulgaris. J Drugs Dermatol 2006; 5 (4): 344-9
34. Sawleshwarkar SN, Salgaonkar V, Oberai CM. Multicenter study to evaluate efficacy and irritation potential of benzoyl peroxide 4%cream in hydrophase base (Brevoxyl) in acne vulgaris. Indian JDermatolVenereol Leprol 2003; 69 (1): 19-22
35. Gold LS. Fixed-combination products in the management of acne vulgaris. Cutis 2010; 85 (3): 160-7
36. Gold MH. A multicenter efficacy and tolerability evaluation of benzoyl peroxide in a 10% urea vehicle for the treatment of acne vulgaris. J Drugs Dermatol 2006; 5 (5): 442-5
37. Jelvehgari M, Siahi-Shadbad MR, Azarmi S, et al. The microsponge delivery system of benzoyl peroxide: preparation, characterization and release studies. Int J Pharm 2006; 308 (1-2): 124-32
38. UK National Health Service Clinical Knowledge Summary. Acne vulgaris, 2009 [online]. Available from URL: http://www.cks.nhs.uk/search?&page= 1&q=acne%20vulgaris&site=0 [Accessed 2011 Apr 13]
39. Kinney MA, Yentzer BA, Fleischer AB, et al. Trends in the treatment of acne vulgaris: are measures being taken to avoid antimicrobial resistance? J Drugs Dermatol 2010; 9 (5): 519-24
40. Chalker DK, Shalita A, Smith JG, et al. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol 1983; 9 (6): 933-6
41. Tschen E. Potential role for a new combination topical therapy in treating mildto moderate acne vulgaris. Cutis 2001; 67 (2 Suppl.): 25-7
42. Leyden J. Are 2 combined antimicrobial mechanisms better than 1 for the treatment of acne vulgaris? Clinical and antimicrobial results of a topical combination product containing 1% clindamycin and 5% benzoyl peroxide. Introduction Cutis 2001; 67 (2 Suppl.): 5-7
43. Thiboutot D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination ofclindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008; 59 (5): 792-800
44. Kircik L, Green L, Thiboutot D, et al. Comparing a novel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin: final data from a multicenter,investigator-blind, randomized study. J Drugs Dermatol 2009; 8 (9): 812-8
45. Langner A, Chu A, Goulden V, et al. A randomized, single-blind comparisonof topical clindamycin + benzoyl peroxide and adapalene in the treatment ofmild to moderate facial acne vulgaris. Br J Dermatol 2008; 158 (1): 122-9
46. Ozolins M, Eady EA, Avery AJ, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris inthe community: randomised controlled trial. Lancet 2004; 364 (9452): 2188-95
47. Seidler E, Kimball AB. Meta-analysis of randomized controlled trials using 5%benzoyl peroxide and clindamycin versus 2.5%benzoyl peroxide and clindamycintopical treatments in acne [abstract]. J Am Acad Dermatol 2011; 64 (2): AB6
48. Bucks D, Angel A, Del Rosso J, et al. Can delivery be enhanced and skinirritation minimized using a lower concentration of benzoyl peroxide in afixed combination product [abstract]? J Am Acad Dermatol 2009; 60 (3):AB16
49. Ozolins M, Eady EA, Avery A, et al. Randomised controlled multiple treatmentcomparison to provide a cost-effectiveness rationale for the selection ofantimicrobial therapy in acne. Health Technol Assess 2005; 9 (1): iii-212
50. Wolf JE, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combinedtopical treatment of acne vulgaris with adapalene and clindamycin: a multicenter,randomized, investigator-blinded study. J Am Acad Dermatol 2003;49 (3 Suppl.): S211-7
51. Gollnick HP, Draelos Z, Glenn MJ, et al. Adapalene-benzoyl peroxide,a unique fixed-dose combination topical gel for the treatment of acne vulgaris:a transatlantic, randomized, double-blind, controlled study in 1670 patients.Br J Dermatol 2009; 161 (5): 1180-9
52. NilFroushzadeh MA, Siadat AH, Baradaran EH, et al. Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in thetopical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian J Dermatol Venereol Leprol 2009; 75 (3): 279-82
53. Rietschel RL, Duncan SH. Clindamycin phosphate used in combination with tretinoin in the treatment of acne. Int J Dermatol 1983; 22 (1): 41-3
54. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind,controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acnevulgaris. J Am Acad Dermatol 2006; 54 (1): 73-81
55. Leyden J, Wortzman M, Baldwin EK. Tolerability of clindamycin/tretinoin gel vs. tretinoin microsphere gel and adapalene gel. J Drugs Dermatol 2009; 8 (4): 383-8
56. Draelos Z, Tanghetti E. Optimizing the use of trazarotene for the treatment offacial acne vulgaris: a multicenter, double-blinded, randomized parallelgrouptrial. Cutis 2002; 69 (2 Suppl.): 20-29
57. Tanghetti E, Dhawan S, Torok H, et al. Tazarotene 0.1 percent cream plusclindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin1 percent gel in the treatment of facial acne vulgaris. Dermatol Online J 2007;13 (3): 1
58. Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied incombination with topical antimicrobial agents. J Am Acad Dermatol 2003;49 (3 Suppl.): S227-32
59. Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstratethe efficacy and safety of dapsone gel, 5% for the treatment of acnevulgaris. J Am Acad Dermatol. 2007; 56 (3): 439.e1-10
60. Piette WW, Taylor S, Pariser D, et al. Hematologic safety of dapsone gel,5%, for topical treatment of acne vulgaris. Arch Dermatol 2008; 144 (12):1564-70
61. Fleischer AB, Shalita A, Eichenfield LF, et al. Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for thetreatment of acne vulgaris: a 12-week, randomized, double-blind study.J Drugs Dermatol 2010; 9 (1): 33-40
62. Pazoki-Toroudi H, Nilforoushzadeh MA, Ajami M, et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. CutanOcul Toxicol 2011 Dec; 30 (4): 286-91
63. Pazoki-Toroudi H, Nassiri-Kashani M, Tabatabaie H, et al. Combinationof azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris.J Dermatolog Treat 2010; 21 (3): 212-6
64. Langner A, Sheehan-Dare R, Layton A. A randomized, single-blind comparisonof topical clindamycin + benzoyl peroxide (Duac) and erythromycin +zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris.J Eur Acad Dermatol Venereol 2007; 21 (3): 311-9
65. Draelos ZD. The multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in the treatment of inflammatory facial dermatoses. J DrugsDermatol 2010; 9 (3): 234-6
66. Seidler EM, Kimball AB. Meta-analysis comparing efficacy of benzoyl peroxide,clindamycin, benzoyl peroxide with salicylic acid, and combinationbenzoyl peroxide/clindamycin in acne. J Am Acad Dermatol 2010; 63 (1):52-62
67. Graupe K, Cunliffe WJ, Gollnick HP, et al. Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinicaltrials and experimental reports. Cutis 1996; 57 (1 Suppl.): 20-35
68. Thiboutot D. Versatility of azelaic acid 15% gel in treatment of inflammatory acne vulgaris. J Drugs Dermatol 2008; 7 (1): 13-6
69. Burkhart CG, Burkhart CN. Treatment of acne vulgaris without antibiotics: tertiary amine-benzoyl peroxide combination vs. benzoyl peroxide alone (Proactiv Solution). Int J Dermatol 2007; 46 (1): 89-93
70. Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically releVant? Implications of resistance for acne patientsand prescribers. Am J Clin Dermatol 2003; 4 (12): 813-31
71. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003; 206 (1): 54-6
72. Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemicantibiotics. Med J Aust 1998; 169 (5): 259-61
73. Coates P, Vyakrnam S, Eady EA, et al. Prevalence of antibiotic- resistantpropionibacteria on the skin of acne patients: 10-year surveillance data andsnapshot distribution study. Br J Dermatol 2002; 146 (5): 840-8
74. Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons fromEurope. Br J Dermatol 2003; 148 (3): 467-78
75. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management ofacne: an update from the Global Alliance to Improve Outcomes in Acnegroup. J Am Acad Dermatol 2009; 60 (5 Suppl.): S1-50
76. Nast A, Bayerl C, Borelli C, et al. S2k-guideline for therapy of acne [in German]. J Dtsch Dermatol Ges 2010; 8 Suppl. 2: s1-59
77. Patel M, Bowe WP, Heughebaert C, et al. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. J Drugs Dermatol 2010; 9 (6): 655-64
78. Handojo I. The combined use of topical benzoyl peroxide and tretinoin in the treatment of acne vulgaris. Int J Dermatol 1979; 18 (6): 489-96
79. Shalita AR, Rafal ES, Anderson DN, et al. Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide6%cleanser for the treatment of acne vulgaris. Cutis 2003; 72 (2): 167-72
80. Thiboutot DM, Weiss J, Bucko A, et al. Adapalene-benzoyl peroxide, a fixeddose combination for the treatment of acne vulgaris: results of a multicenter,randomized double-blind, controlled study. J Am Acad Dermatol 2007;57 (5): 791-9
81. Leyden JJ, Preston N, Osborn C, et al. In-vivo effectiveness of adapalene0.1%/benzoyl peroxide 2.5% gel on antibiotic-sensitive and resistant Propionibacteriumacnes. J Clin Aesthet Dermatol 2011; 4 (5): 22-6
82. Jackson JM, Fu JJ, Almekinder JL. A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1%gel comparedwith a clindamycin phosphate 1.2%/tretinoin 0.025%gelin the topical treatment of acne vulgaris. J Drugs Dermatol 2010; 9 (2): 131-6
83. Bowman S, Gold M, Nasir A, et al. Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acnevulgaris: a randomized, blinded study. J Drugs Dermatol 2005; 4 (5): 611-8
84. Nast A, Dreno B, Bettoli V, et al. European evidence based (S3) guideline for treatment of acne (ICD L70.0). EU Acne Guidelines Group; draft version13/5/2011 [online]. Available from URL: http://www.acne-guideline.com/ home-eu/External-open-review/ [Accessed 2011 May 28]
85. Acne Working Group. Management of mild and moderate acne vulgaris. GPReview 2008 Jan 1-11
86. Alexis AF. Clinical considerations on the use of concomitant therapy in the treatment of acne. J Dermatolog Treat 2008; 19 (4): 199-209
87. Gupta AK, Lynde CW, Kunynetz RA, et al. A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topicalgels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/ erythromycin 4% in the treatment of moderate acne vulgaris of the face. J CutanMed Surg 2003; 7 (1): 31-7
88. Burkhart CG, Scheinfeld NS. Benzoyl peroxide skin washes: basis, logic, effectiveness,and tolerance. Skinmed 2005; 4 (6): 370
89. Kraus AL, Munro IC, Orr JC, et al. Benzoyl peroxide: an integrated humansafety assessment for carcinogenicity. Regul Toxicol Pharmacol 1995; 21 (1):87-107
90. Rothman KF, Pochi PE. Use of oral and topical agents for acne in pregnancy. J Am Acad Dermatol 1988; 19 (3): 431-42
91. Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycinphosphate. Arch Dermatol 1986; 122 (5): 583-4
92. Yentzer BA, Ade RA, Fountain JM, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomizedcontrolled trial. Cutis 2010; 86 (2): 103-8
93. Bikowski J. A review of the safety and efficacy of benzoyl peroxide (5.3%)emollient foam in the management of truncal acne vulgaris. J Clin AesthetDermatol 2010; 3 (11): 26-9
94. Nguyen D, Ornstein C, Weber T. Dollars for docs: how industry dollars reachyour doctors [online]. Available from URL: http://projects.propublica.org/ docdollars/ [Accessed 2011 Sep 15]